These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 28279217)

  • 1. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.
    Kearney K; Tomlinson D; Smith K; Ajjan R
    Cardiovasc Diabetol; 2017 Mar; 16(1):34. PubMed ID: 28279217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation.
    Bryk-Wiązania AH; Undas A
    Cardiovasc Diabetol; 2021 Sep; 20(1):191. PubMed ID: 34551784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.
    Ten Cate H; Guzik TJ; Eikelboom J; Spronk HMH
    Cardiovasc Res; 2021 Jul; 117(9):2030-2044. PubMed ID: 32931586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future Antithrombotic Therapies in Cardiology.
    Bäuml M; Hilgendorf I
    Hamostaseologie; 2018 Nov; 38(4):236-239. PubMed ID: 30267387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation and fibrinolysis in diabetes.
    Alzahrani SH; Ajjan RA
    Diab Vasc Dis Res; 2010 Oct; 7(4):260-73. PubMed ID: 20847109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis in Acute and Chronic Cardiovascular Disease.
    Kietsiriroje N; Ariëns RAS; Ajjan RA
    Semin Thromb Hemost; 2021 Jul; 47(5):490-505. PubMed ID: 33878782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus.
    Soma P; Pretorius E
    Cardiovasc Diabetol; 2015 Jul; 14():96. PubMed ID: 26228646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
    Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
    Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
    Kruger PC; Eikelboom JW; Yusuf S
    Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombotic therapy in diabetes: which, when, and for how long?
    Ajjan RA; Kietsiriroje N; Badimon L; Vilahur G; Gorog DA; Angiolillo DJ; Russell DA; Rocca B; Storey RF
    Eur Heart J; 2021 Jun; 42(23):2235-2259. PubMed ID: 33764414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis in diabetes: a shear flow effect?
    Westein E; Hoefer T; Calkin AC
    Clin Sci (Lond); 2017 Jun; 131(12):1245-1260. PubMed ID: 28592700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks.
    Martins Lima A; Martins Cavaco AC; Fraga-Silva RA; Eble JA; Stergiopulos N
    Thromb Haemost; 2019 Nov; 119(11):1720-1739. PubMed ID: 31564053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fibrin network in diabetes: its role in thrombosis risk.
    Kurdee Z; King R; Ajjan RA
    Pol Arch Med Wewn; 2014; 124(11):617-27. PubMed ID: 25379971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation and thrombosis in diabetes.
    Hess K; Grant PJ
    Thromb Haemost; 2011 May; 105 Suppl 1():S43-54. PubMed ID: 21479339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
    Gaule TG; Ajjan RA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.
    Pechlivani N; Kearney KJ; Ajjan RA
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microfluidic Modeling of Thrombolysis.
    Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
    Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen and catheter-directed thrombolysis.
    Ross RL; Beck AW
    Semin Vasc Surg; 2014 Dec; 27(3-4):182-95. PubMed ID: 26073829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.